TABLE 2.
Treatment, supportive care and outcomes
| n (%) a | ||
|---|---|---|
| Pediatric, N = 22 | Obstetric, N = 10 | |
| Treatments b | ||
| Remdesivir | 20 (90.9) | 9 (90) |
| Azithromycin | 10 (45.5) | 10 (100) |
| Antibiotics | 22 (100) | 10 (100) |
| Vasopressors | 8 (36.4) | 1 (10) |
| Heparin or enoxaparin | 18 (81.8) | 10 (100) |
| Anakinra | 5 (22.7) | 0 (0) |
| Dexamethasone | 20 (90.9) | 10 (100) |
| Betamethasone | 0 | 7 (70) |
| Respiratory support | ||
| Invasive mechanical ventilation | 10 (45.5) | 2 (20) |
| BiPAP/CPAP | 16 (72.7) | 0 (0) |
| High flow nasal cannula | 15 (68.2) | 7 (70) |
| Low flow oxygen | 11 (50) | 7 (70) |
| VV‐ECMO | 1 (4.5) | 1 (10) |
| VA‐ECMO | 2 (9.1) | 0 (0) |
| Duration of hospitalization days [median, (range)] | 18 (5–117) c | 8 (5–14) |
| Duration of ICU admission days [median, (range)] | 15.5 (5–42) | 4.5 (2–14) d |
| Discharged | 17 (77.3) | 10 (100) |
| Deceased | 5 (22.7) | 0 |
| New diagnosis/problem e | ||
| Pneumonia | 19 (86.4) | 10 (100) |
| Respiratory failure | 22 (100) | 10 (100) |
| Lymphocytopenia | 21 (95.5) | 10 (100) |
| Thrombocytopenia | 13 (59.1) | 1 (10) |
| ARDS | 3 (13.6) | 1 (10) |
| Cardiogenic shock | 2 (9.1) | 0 |
| Acute kidney injury | 7 (31.8) | 0 |
| Increased transaminases | 11 (50) | 5 (50) |
| Myocarditis | 1 (4.5) | 0 |
| Dilation of coronary artery | 4 (18.2) | 0 |
Note: Lymphocytopenia defined as absolute lymphocyte count <1000 for adults and <1500 for children 18 and under, thrombocytopenia defined as platelet count less than 150,000/mcl, ARDS defined per Berlin definition for clinical diagnosis, AKI defined as increase in creatinine of 0.3 mg/dl within 48 h and increased transaminases defined as three times upper limit of normal for AST and ALT.
Abbreviations: ARDS, acute respiratory distress syndrome; BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; VA‐ECMO, veno‐arterial extracorporeal membrane oxygenation; VV‐ECMO, veno‐venous extracorporeal membrane oxygenation.
Unless otherwise specified.
For pediatrics, additional treatments used include: hydroxychloroquine for systemic lupus erythematosus in one patient, intravenous immune globulin (IVIG) in two patients, canakinumab in one patient and bivalirudin in two patients.
The patient admitted for 117 days had prolonged hospitalization due to problems related to worsening complications of his underlying chronic granulomatous disease, which exacerbated upon recovery from acute COVID‐19.
Excludes patients who were not admitted to the ICU.
New diagnosis or problem during admission.